Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study
Movement Disorders Clinical Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 25, 2025
Levodopa-entacapone-carbidopa
intestinal
gel
(LECIG)
was
introduced
in
2018
as
a
device-aided
therapy
for
advanced
Parkinson's
disease
(PD).
The
ELEGANCE
study
(NCT05043103)
is
gathering
real-world
data
on
long-term
efficacy,
safety
and
patient-reported
outcomes
with
LECIG
from
13
European
countries.
This
article
reports
the
planned
interim
analysis.
enrolled
patients
prescribed
part
of
routine
clinical
care.
We
evaluated
at
V1
before
starting
treatment
(in
seven
were
obtained
retrospectively),
thereafter
V2
(3-6
months)
or
V3
(6-12
months).
analysis
includes
167
37
centers.
Three
this
set
(1.8%)
discontinued
study.
Mean
(±SD)
daily
OFF-time
hours
(MDS-UPDRS
IV
item
4.3)
substantially
reduced
by
3.47
±
3.56
h
(baseline:
5.15
3.05;
P
<
0.0001).
Similarly,
MDS-UPDRS
total
scores
4.24
4.08
10.77
3.83);
(P
=
0.0001)
II
3.63
7.76
20.65
8.17;
0.0004).
PDSS-2
sustainably
improved
(reduction
7.38
10.72
[baseline:
25.21
10.62];
0.0001),
PDQ-8
summary
index
score
indicating
an
improvement
quality
life
(QoL)
13.3
19.05
46.34
20.09];
For
all
parameters
improvements
maintained
V3.
Patient-reported
satisfaction
pump
high.
Most
adverse
events
related
to
procedure
device.
Routine
use
up
12
months
provided
sustained
control
motor
symptoms,
well
tolerated
positive
impact
QoL
high
patient
satisfaction.
Language: Английский
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Hannah A. Blair
No information about this author
CNS Drugs,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 8, 2025
Language: Английский
Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease
Clinical Parkinsonism & Related Disorders,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100330 - 100330
Published: April 1, 2025
Language: Английский
The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety
Expert Review of Medical Devices,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 7, 2025
Device-aided
therapies
(DATs)
have
been
developed
to
provide
continuous
drug
delivery
(CDD)
people
with
advanced
Parkinson's
disease
(PD)
whose
symptoms
can
no
longer
be
effectively
managed
oral
or
transdermal
therapy.
Intrajejunal
infusion
of
levodopa
-
carbidopa
intestinal
gel
(LCIG),
delivered
via
the
CADD
Legacy
1400
pump,
is
an
established
CDD
option,
while
entacapone
(LECIG),
Crono
LECIG
a
more
recent
addition
range
DAT
options
in
Europe.
This
article
explores
rationale
for
development
infusion,
role
formulation,
and
attributes
specifications
pump
device.
Clinical
real-world
data
reporting
its
efficacy,
safety
tolerability
PD
patients
from
European
centers
are
reviewed,
focus
on
practical
benefits
that
smaller,
lighter
quieter
device
who
wish
start
treatment
intrajejunal
infusion.
offers
another
valuable
option
consider
suitable
providing
both
good
long-term
clinical
favorable
experience
patients.
Language: Английский
Machine Learning-Empowered Multicolor Detection and Discrimination of Dopaminergic Agents: Utilizing Gold Nanorods for Generating Rainbow Signals
Zahra Hozhabr,
No information about this author
Afsaneh Orouji,
No information about this author
M. Reza Hormozi‐Nezhad
No information about this author
et al.
ACS Applied Nano Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 25, 2024
The
demand
for
rapid
and
sensitive
multianalyte
detection
of
dopaminergic
agents
in
assessing
the
progression
Parkinson's
disease
(PD)
has
attracted
recurring
interest
recent
years.
In
this
study,
a
multicolor
sensor
was
devised
to
multiplex
discrimination
levodopa
(l-DOPA),
carbidopa
(Carbi),
benserazide
(Benz)─key
compounds.
Notably,
presence
inhibits
etching
gold
nanorods
(AuNRs)
by
N-bromosuccinimide
(NBS),
with
varying
degrees
inhibition
depending
on
concentration
properties
analytes.
This
interaction
induces
alterations
size
aspect
ratio
AuNRs,
resulting
red
shift
within
plasmonic
band.
Remarkably,
band
AuNRs
corresponds
color
variations
akin
rainbow
solution,
providing
valuable
opportunity
precise
visual
detection.
Statistical
analysis
collected
data
set
performed
using
two
machine
learning
techniques:
linear
discriminant
(LDA)
pattern
recognition
partial
least-squares
regression
(PLSR)
analysis.
LDA
effectively
discriminated
their
binary
ternary
mixtures
100%
accuracy,
while
PLSR
enabled
quantitative
over
wide
range:
1.17–25.0,
2.63–25.0,
1.18–25.0
μmol
L–1,
limits
0.93,
0.88,
0.39
l-DOPA,
Carbi,
Benz,
respectively.
Furthermore,
we
validated
practical
applicability
assay
identifying
quantifying
agent
medicines
tablets
containing
these
compounds,
affirming
its
utility
reliability
on-site
quality
control.
Language: Английский
Vestibular Neurostimulation for Parkinson’s Disease: A Novel Device-Aided Non-Invasive Therapeutic Option
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(9), P. 933 - 933
Published: Aug. 31, 2024
Dopaminergic
replacement
therapy
remains
the
mainstay
of
symptomatic
treatment
for
Parkinson's
disease
(PD),
but
many
unmet
needs
and
gaps
remain.
Device-based
treatments
or
device-aided
non-oral
therapies
are
typically
used
in
advanced
stages
PD,
ranging
from
stereotactic
deep
brain
stimulation
to
levodopa
apomorphine
infusion
therapies.
But
there
concerns
associated
with
these
late-stage
due
a
number
procedural,
hardware,
long-term
treatment-related
side
effects
treatments,
their
limited
nonmotor
benefit
PD.
Therefore,
is
an
urgent
need
low-risk
adjuvants
standalone
which
can
address
range
burdensome
motor
symptoms
that
occur
Recent
studies
suggest
non-invasive
neurostimulation
vestibular
system
may
be
able
through
brainstem
sensory
network
extensively
innervates
regions,
regulating
both
functions.
Therapeutic
relatively
modern
concept
potentially
improve
broad
even
at
early
disease.
Here,
we
review
previous
supporting
therapeutic
potential
PD
discuss
ongoing
clinical
trials
areas
future
investigations.
Language: Английский
Continuous dopaminergic stimulation and the transition to using continuous drug delivery in Parkinson's disease—An introduction
Peter Jenner
No information about this author
International review of movement disorders,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 1, 2024
Language: Английский
Pharmacological and non-pharmacological management of sleep disturbances in Parkinson’s disease: if when and how
Expert Opinion on Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
25(16), P. 2135 - 2149
Published: Nov. 1, 2024
Introduction
Sleep
dysfunction
occurs
in
various
forms
and
is
a
bothersome
intrusive
non-motor
symptom
of
Parkinson's
disease
(PD).
Frequently
undiagnosed,
their
poor
management
can
have
great
impact
on
the
quality
life
PD
patients
caregivers.
Language: Английский
Challenges of equitable access to device-aided therapies for advanced Parkinson’s Disease in Poland — expert consensus and treatment recommendations
Neurologia i Neurochirurgia Polska,
Journal Year:
2024,
Volume and Issue:
58(6), P. 608 - 616
Published: Dec. 27, 2024
Language: Английский